Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 1 of the last 2 fiscal years.
-
Two loss years in a row NBB
Negative result in 2021 and 2022.
-
Tight liquidity NBB
Cash and receivables cover 18 % of short-term debt in 2022; threshold 65 %.
-
Legal situation KBO
Opening faillissement according to the CBE.
Financials
Financial year 2022
Texere Biotech from Les Bons Villers, company number BE0666661105, closed financial year 2022 with a result of € -825,129 after tax. For that financial year Texere Biotech recorded a gross margin of € 217,567 and equity of € -710,144. Compared with financial year 2021, the result moved from € -1.1 million to € -825,129. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 1, 2023.
€ -710,144
▼ € 874,811 vs 2021
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -825,129
▲ 27 % less loss than in 2021
Profit after tax over the fiscal year.
€ 206,020
▼ 43% vs 2021
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -4.1 million.
People and assets in 2022
7.9
▲ 0.1 vs 2021
Average over the fiscal year, from the social balance sheet.
€ 493,350
▲ 13% vs 2021
€ 62,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 2.1 million
▲ 161% vs 2021
Of which on lease € 2.1 million.
Debts at end 2022
€ 5.9 million
▲ 81% vs 2021
€ 608,387 is repaid this year. At this pace the long-term loan is gone in ≈ 9 years.
€ 907,696
▲ 14% vs 2021
Supplier invoices still open on the last day of the fiscal year.
€ 43,113
▲ 1% vs 2021
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2021 | 2022 | Change 2021 → 2022 | |
|---|---|---|---|
| Gross margin | € -169,724 | € 217,567 | ▲ € 387,291 |
| Profit after taxes | € -1,124,022 | € -825,129 | ▲ € 298,893 |
| Equity | € 164,668 | € -710,144 | ▼ € 874,811 |
| Total debts | € 4,569,653 | € 6,936,691 | ▲ 52% |
| Cash | € 358,401 | € 206,020 | ▼ 43% |
| Retained profit | € -3,294,540 | € -4,119,670 | ▼ € 825,129 |
| Bank debt | € 3,272,861 | € 5,923,487 | ▲ 81% |
| Balance sheet total | € 4,734,320 | € 6,226,548 | ▲ 32% |
| Employees (FTE) | 7.8 | 7.9 | ▲ 0.1 |
Key figures of Texere Biotech, fiscal years 2021 to 2022, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2023 has not been filed yet; it was expected before 31 July 2024.
What happened to Texere Biotech?
What happened at Texere Biotech in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
Texere Biotech is active according to the CBE. Legal situation: Opening faillissement.
- New annual accounts for financial year 2022: loss of € 825,129. Source: NBB ↗
- François Fontaine became a director. NBB
- Luc Bülhmann became a director. NBB
- New establishment in Les Bons Villers. KBO
- PROGERA SRL became a director. NBB
- THERACELL CONSULTING became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 1.1 million loss in 2021 to € 825,129 loss in 2022.
Paid € 1,584 in corporate taxes since 2021.
On average € 27,500 of value added per employee in 2022.
A new publication or filing at Texere Biotech? We notify you, reason included.
Follow Texere BiotechDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of Theracell Consulting, SOCIETE FEDERALE DE PARTICIPATIONS ET D'INVESTISSEMENT, PROGERA comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
Texere BiotechBehind Texere Biotech are PROGERA SRL, François Fontaine, THERACELL CONSULTING and Luc Bülhmann. The shares are held by Theracell Consulting (29.2%), SOCIETE FEDERALE DE PARTICIPATIONS ET D'INVESTISSEMENT (14.3%) and PROGERA.
Directors
According to the 2022 annual accounts
Director · represented by Jean-Jacques Dufrane
since 2016
François Fontaine
Director
Also active at: COMETSAMBRE, COMET TRAITEMENTS, OncoDNA, EPIMEDE, PDC line Pharma, Newton Biocapital I, pricaf privée de droit belge, Curium PET Liège, EPICS THERAPEUTICS +7 more
since 2020
since 2016
Luc Bülhmann
Director
since 2020
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Rue des Artisans(FLG) 4 box a
6210 Les Bons Villers
Rue des Artisans(FLG) 4 box A
6210 Les Bons Villers
Active since 2 December 2016
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0666.661.105
- VAT number
- BE 0666.661.105
- Registered office
- Rue des Artisans(FLG) 4 bus a, 6210 Les Bons Villers
- Names & denominations
- Texere Biotech
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Opening faillissement
- Start date
- 24 November 2016
- Peppol
- Not registered
- Activities · NACE
Groothandel in andere intermediaire producten, neg
Groothandel in andere intermediaire producten, n.e.g.
Speur- en ontwikkelingswerk op biotechnologisch gebied
Overige zakelijke dienstverlening, neg